BTIG Research Reaffirms “Buy” Rating for Maze Therapeutics (NASDAQ:MAZE)

Maze Therapeutics (NASDAQ:MAZE)‘s stock had its “buy” rating restated by investment analysts at BTIG Research in a research report issued on Tuesday, Benzinga reports. They currently have a $46.00 price target on the stock. BTIG Research’s price objective would indicate a potential upside of 69.53% from the stock’s previous close.

Other analysts have also recently issued reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Wall Street Zen downgraded shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, TD Cowen raised Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Three analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $66.00.

Maze Therapeutics Stock Up 21.2%

Shares of NASDAQ MAZE traded up $4.74 on Tuesday, hitting $27.13. The company had a trading volume of 1,912,152 shares, compared to its average volume of 646,265. Maze Therapeutics has a 12-month low of $21.95 and a 12-month high of $53.65. The business has a 50 day moving average of $27.24 and a two-hundred day moving average of $29.42. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $1.51 billion, a P/E ratio of -10.76 and a beta of 2.17.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.76). As a group, equities research analysts forecast that Maze Therapeutics will post -2.72 earnings per share for the current fiscal year.

Insider Transactions at Maze Therapeutics

In related news, CEO Jason V. Coloma sold 34,501 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $26.29, for a total value of $907,031.29. Following the completion of the transaction, the chief executive officer directly owned 18,151 shares of the company’s stock, valued at approximately $477,189.79. This trade represents a 65.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $27.34, for a total transaction of $205,050.00. Following the transaction, the insider directly owned 26,250 shares of the company’s stock, valued at approximately $717,675. This trade represents a 22.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 191,459 shares of company stock valued at $5,263,539. Company insiders own 5.30% of the company’s stock.

Institutional Trading of Maze Therapeutics

Several institutional investors have recently made changes to their positions in the company. TRV GP IV LLC purchased a new stake in Maze Therapeutics in the 2nd quarter valued at $133,502,907. ARCH Venture Management LLC purchased a new position in shares of Maze Therapeutics during the second quarter valued at $122,983,582. BlackRock Inc. acquired a new position in Maze Therapeutics during the second quarter valued at approximately $104,525,000. Jupiter Topco LLC acquired a new position in shares of Maze Therapeutics during the 2nd quarter worth $101,764,000. Finally, Alphabet Inc. bought a new position in shares of Maze Therapeutics in the 2nd quarter worth $41,435,000.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.